Association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer
Association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer
复制标题
α2a 和 β2 肾上腺素受体表达与乳腺癌临床结果的关联。
DOI：
10.1185/03007995.2014.890928
复制
发表时间：
2014-07-01
影响因子：
2.3
通讯作者：
Lu, Jinsong
中科院分区：
文献类型：
--
作者：
Du, Yueyao;Zhou, Liheng;Lu, Jinsong
背景：α 2肾上腺素受体（α 2 AR）拮抗剂抑制乳腺癌细胞的生长.β 2肾上腺素受体（β 2 AR）对细胞增殖的作用仍然存在争议。在这项研究中，我们研究了α 2a和β 2 AR的表达与肿瘤相关的生物学标志物和临床outcome.Methods：α 2a和β 2 AR的表达在220例手术切除的乳腺肿瘤石蜡包埋标本中检测免疫组化。使用卡方或Fisher精确检验评估AR表达与肿瘤相关生物标志物之间的关联。单变量分析采用Kaplan-Meier曲线，多变量分析采用考克斯检验，并根据年龄、肿瘤大小、淋巴结状态、ER、PR和Her-2状态进行调整。结果：α 2a AR表达与Her-2状态相关（P=0.048），α 2a AR表达与ER之间观察到边际显著性（P=0.061）。在激素受体阳性乳腺癌患者中，β 2 AR强表达与较弱表达相比，（P=0.031）和β 2 AR（HR=0.31，P=0.039）和淋巴结状态（HR=2.85，P=0.031）是DFS的独立预测因素。在激素受体阳性乳腺癌患者中，强β 2 AR表达与比弱β 2 AR表达更好的DFS相关，并且β 2 AR和激素受体途径之间可能存在相互作用。本研究的一些局限性是样本量相对较小和回顾性研究本身的固有性质。该研究的结果仅用于假设，需要在大型前瞻性研究中证实。
Background:Alpha2-adrenoceptor (alpha 2 AR) antagonists inhibit the growth of breast cancer cells. The action of beta2-adrenoceptors (beta 2 AR) on cell proliferation is still controversial. In this study, we investigated the association of alpha 2a and beta 2 AR expression with tumor-relevant biological markers and clinical outcome.Methods:The expression of alpha 2a and beta 2 AR was examined in paraffin-embedded samples of 220 operable breast tumors by immunohistochemistry. Associations between AR expression and tumor-relevant biomarkers were evaluated using the chi-square or Fisher's exact tests. Univariate analysis was modeled using Kaplan-Meier plots and multivariate analysis was modeled using the Cox test and adjusted for age, tumor size, lymph node status, and ER, PR and Her-2 status.Results:The alpha 2a AR expression was associated with Her-2 status (P=0.048) and a marginal significance was observed between alpha 2a AR expression and ER (P=0.061). In hormone receptor positive breast cancer patients, strong beta 2 AR expression correlated with better disease free survival (DFS) than weak expression (P=0.031) and beta 2 AR (HR=0.31, P=0.039) and lymph node status (HR=2.85, P=0.031) were independent predictors of DFS on multivariate analysis.Conclusion:In hormone receptor positive breast cancer patients, strong beta 2 AR expression is correlated with better DFS than weak beta 2 AR expression and an interaction may exist between beta 2 AR and hormone receptor pathways. Some limitations of this study were the relatively small sample size and the intrinsic nature of retrospective study per se. Findings of the study are for hypothesis only and need to be confirmed in large prospective studies.